Citi Depositary Receipt Services Year End 2016 Report

15 / 48

DR ACCESS PRODUCTS
ABOUT CITI DEPOSITARY
RECEIPT SERVICES
INTERNATIONAL
INVESTING TRENDS
REGIONAL TRENDS
GLOBAL DR TRENDS
*Signifies Citi DR program capital raising.
1 Defined as capital raising at the time of listing of additional DR securities
including rights offerings, and private placements.
2 Data as of December 31, 2016.
3 Industry as defined by Bloomberg.
Issuer Country Industry3 USD Value
(in Millions)
International
Ltd China Internet $1,506
GW Pharmaceuticals plc* UK Pharmaceuticals $290
Ros Agro Russia Food $250
ArcelorMittal* Luxembourg Iron/Steel $218
BeiGene, Ltd* China Pharmaceuticals $200
Advanced Accelerator
Applications SA France Health Care Products $172
Ascendis Pharma A/S Denmark Pharmaceuticals $120
Amarin Corp. plc* UK Biotechnology $69
Hinduja Foundries Limited India Auto Parts &
Equipment $60
Sequans Communications SA France Semiconductors $25
Nabriva Therapeutics AG Austria Biotechnology $25
RedHill Biopharma Ltd Israel Pharmaceuticals $24
Nano Dimension Ltd Israel Computers $14
EDAP Technomed SA France Health Care Products $11
Kitov Pharmaceuticals Holdings
Ltd Israel Pharmaceuticals $8
Genetic Technologies Australia Biotechnology $6
Medigus Ltd Israel Health Care Products $1
Samson Oil and Gas Ltd Australia Oil & Gas $1
Grand Total $3,002
DR Follow-On Offerings1,2
Source: Bloomberg and Depositary Data Interchange.
15
Citi Depositary Receipt Services Year-End 2016 Report